Betamethasone

Generic Name: Betamethasone

Brand Names: Betaderm, Betaloan Suik, Beteflam, Celestoderm, Celestone Soluspan, Dermacinrx Therazole Pak, Diprolene, Diprosalic, Diprosone, Dovobet, Enstilar, Fucibet, Lotriderm, Lotrisone, Luxiq, Marbeta, Rivasone, Rolene, Rosone, Sernivo, Taclonex, Valisone-G, Wynzora

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₉FO_₅

CAS Number: 378-44-9

Unique Ingredient Identifier: 9842X06Q6M

Background: Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and negligible mineralocorticoid activity.

Indication: As a member of the corticosteroid family, betamethasone is indicated for the treatment of several inflammatory conditions. As topical monotherapy, betamethasone is indicated to relieve pruritic and inflammatory symptoms of corticosteroid-responsive-dermatoses. Betamethasone can be used topically in combination with a vitamin D analog such as calcipotriene to treat plaque psoriasis. The corticosteroid is also available as an injectable suspension and can be used to manage a range of inflammatory conditions including endocrine disorders, gastrointestinal disorders, and rheumatic disorders among other conditions.

Associated Conditions: Acute Gouty Arthritis, Adrenocortical Insufficiency, Alopecia Areata (AA), Ankylosing Spondylitis (AS), Atopic Dermatitis, Berylliosis, Blepharitis allergic, Blepharoconjunctivitis, Bullous dermatitis herpetiformis, Bursitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Dermatomyositis (DM), Dermatosis, Discoid Lupus Erythematosus (DLE), Edema of the cerebrum, Epicondylitis, Episcleritis, External ear inflammation, Eye allergy, Hypercalcemia of Malignancy, Inflammatory Reaction of the ear, Iridocyclitis, Iritis, Itching caused by Allergies, Keloids Scars, Keratitis, Keratitis interstitial, Keratoconjunctivitis, Leukemias, Lichen Planus (LP), Lichen simplex chronicus, Lupus Erythematosus, Lymphoma, Multiple sclerosis exacerbation, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Nephrotic Syndrome, Ocular Inflammation, Ocular injuries, Ophthalmia, Sympathetic, Pemphigus, Plaque psoriasis of the body, Plaque psoriasis of the scalp, Polymyositis, Post Surgical Ocular Inflammation, Pruritus, Psoriasis, Psoriasis Vulgaris (Plaque Psoriasis), Psoriatic Arthritis, Psoriatic plaque, Pulmonary Tuberculosis (TB), Pure Red Cell Aplasia, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Scleritis, Secondary thrombocytopenia, Severe Asthma, Severe Atopic Dermatitis, Skin Infections, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Temporal Arteritis, Trichinosis, Tuberculous Meningitis, Ulcerative Colitis, Uveitis, Verrucous Lichen Planus (LP), Acquired immune hemolytic anemia, Acute nonspecific tenosynovitis, Acute rheumatic carditis, Bacterial blepharitis, Corticosteroid-responsive dermatoses, Eczematous rash, Exfoliative erythroderma, Granuloma annulare lesions, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Allergic rhinitis, Severe Contact dermatitis, Severe Serum sickness, Severe Transfusion Reactions, Severe drug hypersensitivity reactions, Superficial ocular infections, Symptomatic Sarcoidosis, Synovitis of osteoarthritis

Associated Therapies: -

Clinical Trials

The Effect of Central Sensitization in Radicular Pain in Patients With Failed Low Back Surgery Syndrome

Completed

Conditions: Failed Back Surgery Syndrome
Herniated Disc

Interventions: Drug: Betametasona

First Posted Date: 2024-07-18

Last Posted Date: 2024-08-09

Lead Sponsor: Marmara University

Target Recruit Count: 1

Registration Number: NCT06508918

Locations: 🇹🇷
Mamara Üniversitesi Tıp Fakültesi, Istanbul, Turkey
🇹🇷
Marmara University Pendik Training and Research Hospital, Istanbul, Turkey

Metformin Repurposing in Oral Submucous Fibrosis: Unveiling In Vitro Signaling Pathways, Progressing to Clinical Trial

Phase 1

Not yet recruiting

Conditions: Oral Submucous Fibrosis

Interventions: Drug: Metformin Hydrochloride
Drug: betamethasone dipropionate
Drug: Pentoxifylline

First Posted Date: 2024-03-27

Last Posted Date: 2024-07-26

Lead Sponsor: Ziauddin University

Target Recruit Count: 30

Registration Number: NCT06332612

Locations: 🇵🇰
Ziauddin University, Karachi, Sindh, Pakistan

Comparison of the Efficacy of Phenol Block and Corticosteroid-Local Anesthetic Block Applied to the Genicular Nerve

Not Applicable

Recruiting

Conditions: Knee Osteoarthritis

Interventions: Drug: Phenol
Drug: Celestone
Drug: Lidocain

First Posted Date: 2024-02-20

Last Posted Date: 2024-02-20

Lead Sponsor: Gaziler Physical Medicine and Rehabilitation Education and Research Hospital

Target Recruit Count: 88

Registration Number: NCT06265675

Locations: 🇹🇷
Gaziler, Ankara, Çankaya, Turkey

Efficacy of CTM for Tennis ELbow

Phase 2

Conditions: Lateral Elbow Tendinopathy
Tennis Elbow
Lateral Epicondylitis \(Tennis Elbow\)

Interventions: Device: CTM
Drug: Celestone

First Posted Date: 2023-12-14

Last Posted Date: 2024-03-27

Lead Sponsor: Indiana Hand to Shoulder Center

Target Recruit Count: 54

Registration Number: NCT06171555

Locations: 🇺🇸
Indiana Hand to Shoulder Center, Indianapolis, Indiana, United States

Efficacy and Safety of Timolol for TKI Induced Paronychia

Phase 3

Recruiting

Conditions: Paronychia

Interventions: Drug: Topical Timolol
Drug: Betamethasone Valerate

First Posted Date: 2023-11-18

Last Posted Date: 2023-12-20

Lead Sponsor: Queen Mary Hospital, Hong Kong

Target Recruit Count: 40

Registration Number: NCT06140186

Locations: 🇭🇰
Queen Mary Hospital, Hong Kong, Hong Kong

Antenatal Corticosteroid Therapy: Which Impact on Birth Parameters?

Completed

Conditions: Growth Retardation

Interventions: Drug: Betamethasone

First Posted Date: 2022-12-07

Last Posted Date: 2022-12-12

Lead Sponsor: Central Hospital, Nancy, France

Target Recruit Count: 363

Registration Number: NCT05640596

Excimer Laser With Topical Agents in Psoriasis Vulgaris

Phase 4

Not yet recruiting

Conditions: Psoriasis

Interventions: Device: 308nm Excimer laser
Drug: Tazarotene Topical Gel
Drug: Betamethasone Valerate

First Posted Date: 2022-09-27

Last Posted Date: 2022-10-18

Lead Sponsor: Assiut University

Target Recruit Count: 30

Registration Number: NCT05555797

Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation

Phase 2

Recruiting

Conditions: Skin Inflammation
Allergic Contact Dermatitis

Interventions: Drug: Squaric Acid Dibutyl Ester
Other: Known patch test allergens
Device: Microneedle
Drug: Dupilumab
Device: Suction blistering
Drug: Adalimumab
Procedure: Skin punch biopsy
Drug: Ustekinumab
Drug: Guselkumab
Drug: Canakinumab
Drug: Sarilumab
Drug: Triamcinolone Acetonide
Drug: Betamethasone Valerate
Drug: Fluticasone Propionate

First Posted Date: 2022-09-10

Last Posted Date: 2024-05-23

Lead Sponsor: John Harris

Target Recruit Count: 45

Registration Number: NCT05535738

Locations: 🇺🇸
University of Massachusetts Chan Medical School, Worcester, Massachusetts, United States

Differences in Flare Reaction Incidence and Intensity Following Trigger Finger Injections

Phase 4

Completed

Conditions: Trigger Finger

Interventions: Drug: Betamethasone
Drug: Methylprednisolone

First Posted Date: 2021-05-25

Last Posted Date: 2023-06-23

Lead Sponsor: West Virginia University

Target Recruit Count: 66

Registration Number: NCT04900220

Locations: 🇺🇸
WVU Medicine University Town Center, Morgantown, West Virginia, United States
🇺🇸
Ruby Memorial Hospital or Other WVU Healthcare Site, Morgantown, West Virginia, United States

Comparative Effect of Nigella Sativa and Conventional Management for OSMF

Phase 3

Completed

Conditions: Oral Submucous Fibrosis

Interventions: Dietary Supplement: Nigella sativa oil
Drug: Betamethasone Valerate

First Posted Date: 2020-07-20

Last Posted Date: 2022-03-15

Lead Sponsor: Ziauddin University

Target Recruit Count: 39

Registration Number: NCT04476420

Locations: 🇵🇰
Ziauddin University, Clifton, Karachi, Sindh, Pakistan

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy